Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
11 hedge funds and large institutions have $110K invested in Evofem Biosciences, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
27% less funds holding
Funds holding: 15 → 11 (-4)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
68% less capital invested
Capital invested by funds: $347K → $110K (-$237K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$12.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$4.63K |
| 3 |
Morgan Stanley
New York
|
+$425 |
| 4 |
BlackRock
New York
|
+$193 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$30K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$23K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$18K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$12.1K |
| 5 |
Goldman Sachs
New York
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $55K | -$12.1K | -314 | -19% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $15K | – | – | – |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $14K | +$12.8K | +331 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $11K | +$4.63K | +120 | +86% |
|
5
Northern Trust
Chicago,
Illinois
| $5K | – | – | – |
|
|
CCG
6
Ceeto Capital Group
Coral Gables,
Florida
| $4.7K | +$4.29K | +111 | New |
|
|
7
BlackRock
New York
| $4K | +$193 | +5 | +6% |
|
|
WAS
8
WESPAC Advisors SoCal
Pasadena,
California
| $1K | – | – | – |
|
|
9
Renaissance Technologies
New York
| – | -$30K | -623 | Closed |
|
|
10
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$23K | -490 | Closed |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$18K | -363 | Closed |
|
|
12
Goldman Sachs
New York
| – | -$7K | -146 | Closed |
|
|
AIM
13
Acrospire Investment Management
Chicago,
Illinois
| – | -$1K | -23 | Closed |
|
|
RIA
14
RPG Investment Advisory
Pleasanton,
California
| – | -$1K | -14 | Closed |
|
|
15
Morgan Stanley
New York
| – | +$425 | +11 | New |
|
EVFM Hedge Fund Activity: Q3 2017 in Review
11 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q3 2017, worth a combined $110K — down 68% from $347K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of EVFM and 3 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $12.8K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $30K sold.
- 11 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q3 2017, down from 15 in Q2 2017.
- Funds reported $110K of Evofem Biosciences, Inc. Common Stock stock for Q3 2017, down 68% quarter-over-quarter.
- 3 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q3 2017 and 6 closed out, a net change of -3 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q3 2017 was Susquehanna International Group, an estimated $12.8K added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q3 2017 was Renaissance Technologies, an estimated $30K sold.
Based on aggregated 13F filings for Q3 2017.